Skip to main content
Signal8

ReNeuron Group plc (RNUGF)

ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived exosomes, which are microscopic packages of biological information released by CTX cells, and these are presently in the preclinical research stage. The company also offers licenses for its proprietary ReNcell product line. Demonstrating a commitment to collaborative research, ReNeuron has partnered with University College London to explore methods for generating immune cells from induced pluripotent stem cells, with the ultimate goal of developing novel anti-cancer cell therapies. Established in 1997, ReNeuron Group plc is headquartered in Pencoed, United Kingdom.

Sector: Biotechnology

Industry: Biotechnology

ReNeuron Group plc logo

ReNeuron Group plc

OTC:RNUGFHealthcare
Mkt Cap-
EV-
Float46.43M
O/S57.17M
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 46.43M · FMP free float

899
Oct 30 (18d)prev 899– 0.0%
999.99
Oct 30 (18d)prev 999.99– 0.0%
Borrow (IBKR)

The cost to borrow RNUGF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 2026899 sh
Oct 15, 2026899 sh
Sep 30, 2026899 sh
Sep 15, 2026899 sh
Aug 31, 2026899 sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

FINRA publishes no off-exchange short volume for this symbol.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for RNUGF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 899 RNUGF shares were sold short (<0.01% of a 46.43M-share float, 999.99 days to cover).